Sidoti Has Negative Outlook for USNA FY2026 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti dropped their FY2026 EPS estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, November 4th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.55 for the year, down from their prior estimate of $0.76. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.55 per share.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.22). USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%. The business had revenue of $205.89 million for the quarter, compared to the consensus estimate of $217.42 million.

A number of other equities analysts have also recently issued reports on the company. Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, September 21st. Finally, Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

USANA Health Sciences Stock Down 3.3%

Shares of USANA Health Sciences stock opened at $13.86 on Friday. The business has a fifty day simple moving average of $14.61 and a 200 day simple moving average of $17.99. The stock has a market cap of $256.05 million, a PE ratio of -12.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. USANA Health Sciences has a 12 month low of $12.57 and a 12 month high of $23.59.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of USANA Health Sciences in the second quarter valued at approximately $33,182,000. Pzena Investment Management LLC bought a new stake in shares of USANA Health Sciences during the second quarter worth $25,739,000. Nantahala Capital Management LLC acquired a new stake in shares of USANA Health Sciences during the second quarter worth $17,295,080. Algert Global LLC raised its holdings in shares of USANA Health Sciences by 91.8% during the second quarter. Algert Global LLC now owns 131,758 shares of the company’s stock worth $2,813,000 after acquiring an additional 63,074 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of USANA Health Sciences during the first quarter worth $1,265,000. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences News Roundup

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.